A randomized controlled study on the treatment of perimenopausal syndrome with Jinfeng Pills combined with Femoston based on the NF-?B/IL-1ß/IL-18 pathway

INTERVENTION: Experimental group:Jinfeng Pills Fenmatong;Control group:Jinfeng Pill placebo Fenmatong; CONDITION: Perimenopausal Syndrome PRIMARY OUTCOME: Efficacy Assessment of Traditional Chinese Medicine;Serum levels of IL‐1ß, IL‐18, TNF‐a, and NF‐?B;Serum FSH and E2 levels;Pre‐ and post‐treatment scores of menopausal symptoms in women (modified Kupperman index), pre‐ and post‐treatment scores of menopausal syndrome (traditional Chinese medicine) assessment scale, Pittsb; SECONDARY OUTCOME: Liver and kidney function;Complete Blood Count; INCLUSION CRITERIA: (1) Participants who meet the diagnostic criteria for perimenopausal syndrome in Western medicine and for kidney yang deficiency syndrome in Traditional Chinese Medicine; (2) Female participants aged 40 to 55 years (including 40 and 55 years old); (3) No contraindications for hormone therapy; (4) No history of hormone therapy in the past si Xmonths; (5) Able to complete questionnaires independently; (6) Voluntarily willing to participate in the trial and sign the informed consent form. All of the above conditions must be met simultaneously.